Summary & Overview
CPT 96417: Add-On Intravenous Infusion for Sequential Chemotherapy
Headline: CPT 96417: Add‑On Intravenous Infusion for Sequential Chemotherapy
Lead: CPT 96417 identifies an add‑on procedure for continued intravenous infusion when a different chemotherapy drug is administered following a primary chemotherapy dose. The code captures sequential infusion events during a single treatment encounter and is commonly used in oncology infusion settings.
CPT 96417 represents a focused billing descriptor for highly complex drug or biologic infusion that follows an initial chemotherapy administration. Nationally, accurate use of this add‑on code matters for distinguishing multiple sequential infusions during one visit, ensuring clinical events are documented and billed distinctly from primary infusion codes. The code is relevant across outpatient infusion centers, hospital outpatient clinics, and physician offices where multi‑drug chemotherapy regimens are delivered.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn the clinical and billing context for CPT 96417, how it relates to initial and additional infusion services, and the typical care settings where it applies. The publication provides benchmarks and policy context for coding practice, clarifies common use cases, and summarizes cross‑payer considerations and coverage patterns. Data not available in the input for payer-specific reimbursement rates or state-specific policy variations.
CPT Code Overview
CPT 96417 describes an add-on chemotherapy administration procedure in which a provider continues administration of a chemotherapy drug into a vein using an infusion technique. This code is used to report the administration of a different chemotherapy drug delivered via intravenous infusion following the administration of a primary dose of chemotherapy.
Service type: Chemotherapy administration – add-on infusion (Medicine services and procedures)
Typical site of service: Infusion center or outpatient hospital clinic (typically POS 22), or office (POS 11)
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with metastatic colon cancer (C18.9) presents to an outpatient infusion center (POS 22) for scheduled chemotherapy. The oncology team administers an initial intravenous infusion of a chemotherapy agent using code 96413. Following completion of the primary drug infusion, the provider continues administration of a second, different chemotherapy agent via intravenous infusion and documents the continuation as an add-on administration using 96417. The encounter occurs in an infusion center staffed by an oncology nurse practitioner (taxonomy 163WX0200X) under the oversight of a medical oncologist (taxonomy 207RX0202X). The facility documents start and stop times, drugs administered, and sequencing of doses to support reporting of the primary infusion and the subsequent add-on infusion.
Coding Specifications
-
Common Modifiers
-
EJ: Subsequent dose in a series — used to distinguish between an initial and a subsequent dose of the same drug when multiple sequential doses are administered. -
Provider Taxonomies
| Taxonomy Code | Specialty |
|---|---|
207RH0003X | Hematology & Oncology Physician |
207RX0202X | Medical Oncology Physician |
163WX0200X | Oncology Nurse Practitioner |
Related Diagnoses
-
C50.911— Malignant neoplasm of unspecified site of right female breast- Clinical relevance: Breast cancer is a common indication for systemic chemotherapy;
96417may be used when a secondary chemotherapy agent is administered after the primary infusion during the same visit.
- Clinical relevance: Breast cancer is a common indication for systemic chemotherapy;
-
C34.90— Malignant neoplasm of unspecified part of unspecified bronchus or lung- Clinical relevance: Lung cancer often requires multi‑agent intravenous chemotherapy regimens; an add‑on infusion code like
96417documents administration of a subsequent different agent.
- Clinical relevance: Lung cancer often requires multi‑agent intravenous chemotherapy regimens; an add‑on infusion code like
-
C18.9— Malignant neoplasm of colon, unspecified- Clinical relevance: Colorectal malignancies are treated with combination regimens where
96417may capture the second agent given via IV infusion after the initial drug.
- Clinical relevance: Colorectal malignancies are treated with combination regimens where
-
C61— Malignant neoplasm of prostate- Clinical relevance: Advanced prostate cancer regimens sometimes include intravenous agents;
96417applies when a different chemotherapy or complex biologic is administered following the primary infusion.
- Clinical relevance: Advanced prostate cancer regimens sometimes include intravenous agents;
-
C25.9— Malignant neoplasm of pancreas, unspecified- Clinical relevance: Pancreatic cancer treatment frequently uses multi‑agent IV chemotherapy;
96417is relevant for documenting the additional agent administered after the primary dose.
- Clinical relevance: Pancreatic cancer treatment frequently uses multi‑agent IV chemotherapy;
Related CPT Codes
| CPT Code | Description |
|---|---|
96413 | Initial chemotherapy administration, intravenous infusion technique; up to 1 hour |
96415 | Chemotherapy administration, intravenous infusion technique; each additional hour (same drug) |
-
Relationship to
96417: -
96413is reported for the primary intravenous infusion (up to 1 hour) before reporting the add-on infusion with96417when a different chemotherapy drug is administered through the same intravenous infusion technique. -
96415is reported for each additional hour of infusion for the same drug; it is used when the primary drug requires extended infusion time and may be billed with96413and, when applicable, with96417to reflect additional infusion duration for the same drug or sequencing within the overall chemotherapy session. -
Common usage:
96413followed by96417when a different agent is continued via infusion;96415is used for additional time increments of the same drug.
National Reimbursement Benchmarks
Medicare's national mean rate for CPT 96417 is $69.34, which is substantially lower than the BUCA (average commercial) mean of $99.01. This gap of $29.67 indicates a meaningful separation between federal reimbursement levels and commercial market averages for this code.
Dispersion measured as the interquartile range (P75 − P25) varies across payers. Cigna has the widest spread (134 − 76 = 58), followed by UnitedHealth Group (126 − 71 = 55) and Blue Cross Blue Shield (115 − 75 = 40). Aetna (94 − 65 = 29) and BUCA (111 − 71.75 = 39.25) show moderate dispersion. Medicare is the tightest with a spread of 9 (72 − 63 = 9). The table and chart below present the full numerical breakdown for national benchmarks.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.